BioCentury
ARTICLE | Clinical News

PA21 regulatory update

February 18, 2013 8:00 AM UTC

Galenica's specialty pharma business Vifor Pharma Ltd. submitted an NDA to FDA for PA21 to treat hyperphosphatemia in patients with chronic kidney disease (CKD). Separately, EMA accepted for review an...